Kymab | pharmaphorum

Kymab

News

Sanofi Headquarters in Paris

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

News

Sanofi Headquarters in Paris

Sanofi buys UK's Kymab and inflammatory disease hopeful for ...

Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big French pharma seeks to add to its pipeline of drugs that treat inflammatory diseases and cancer.

News

babylon-health

Record number of health firms feature in UK top 100 private ...

A record number of health and medtech companies have been included in the Sunday Times Sage Tech Track 100, which ranks Britain’s private tech companies.

News

Kymab signs immuno-oncology deal for bi-specific antibodies

UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field.

News

HIV budding Color

UK's Kymab could help develop HIV vaccine

UK biotech Kymab could help develop a new approach to vaccinating against HIV, according to research published in the journal, Science.

Views & Analysis

Biotech 600

Will the UK ever produce a world-class biotech company?

The sale of microchip company ARM Holdings has some lamenting the loss of that rare thing, a British world-class company.